Cancer and radiation therapy: Current advances and future directions

International Journal of Medical Sciences

Volumn 9, Issue 3, 2012, Pages 193-199

  Baskar, Rajamanickam ^a   Lee, Kuo Ann ^a   Yeo, Richard ^a   Yeoh, Kheng Wei ^a  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

Author keywords

Cancer; Cell death; Linear energy transfer; Radiation therapy

Indexed keywords

APOPTOSIS; AUTOPHAGY; CANCER CELL; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL KILLING; COMPUTER ASSISTED RADIOTHERAPY; HUMAN; IMAGE GUIDED RADIOTHERAPY; INTENSITY MODULATED RADIATION THERAPY; PARTICLE RADIATION; PHOTON THERAPY; RADIATION DOSE FRACTIONATION; RADIATION RESPONSE; REVIEW; STEREOTACTIC TREATMENT;

APOPTOSIS; AUTOPHAGY; DNA DAMAGE; DOSE FRACTIONATION; HUMANS; NEOPLASMS; PHOTONS; RADIOSURGERY; RADIOTHERAPY, CONFORMAL; RADIOTHERAPY, IMAGE-GUIDED; RADIOTHERAPY, INTENSITY-MODULATED;

EID: 84863264554     PISSN: 14491907     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijms.3635     Document Type: Review

References (58)

1. International Agency for Research on Cancer (IARC): GLOBOCAN 2008, Cancer incidence and mortality worldwide. Lyon, France: IARC. 2010.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin. 2011; 61: 69-90.
3. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-2917.
4. Hanahan D, Weinberg R: The hallmarks of cancer. Cell 2000; 100: 57-70.
5. Chaffer CL, Weinberg RA: A perspective on cancer cell metastasis. Science 2011; 331: 1559-1564.
6. Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. Cell 2011; 44: 646-674.
7. Pollack LA, Rowland JH, Crammer C, Stefanek M: Introduction: charting the landscape of cancer survivors' healthrelated outcomes and care. Cancer 2009; 115: 4265-4269.
8. Ringborg U, Bergqvist D, Brorsson B, Cavallin-Ståhl E, Ceberg J, Einhorn N, Frödin JE, Järhult J, Lamnevik G, Lindholm C, Littbrand B, Norlund A, Nylén U, Rosén M, Svensson H, Möller TR: The Swedish Council on Technology Assessment in Health Care: systematic overview of radiotherapy for cancer including a prospective survey of radiotherapy practice in Sweden 2001-summary and conclusions. Acta Oncol. 2003; 42: 357-365.
9. Delaney G, Jacob S, Featherstone C, Barton M: The role of radiotherapy in cancer treatment: estimating optimal utilization from a review of evidence-based clinical guidelines. Cancer 2005; 104: 1129-1137.
10. Begg AC, Stewart FA, Vens C: Strategies to improve radio-therapy with targeted drugs. Nat Rev Cancer 2011; 11: 239-253.
11. Barnett GC, West CM, Dunning AM, Elliott RM, Coles CE, Pharoah PD, Burnet NG: Normal tissue reactions to radiother-apy: towards tailoring treatment dose by genotype. Nat Rev Cancer 2009; 9: 134-142.
12. Bernier J, Hall EJ, Giaccia A: Radiation oncology: a century of achievements. Nature 2004; 4: 737-747.
13. Jackson SP, Bartek J: The DNA-damage response in human biology and disease. Nature 2009; 461: 1071-1078.
14. Bernier J, Hall EJ, Giaccia A: Radiation oncology: a century of achievements. Nature 2004; 4: 737-747.
15. Ellis F: Dose, time and fractionation: a clinical hypothesis. Clin Radiol. 1969; 20: 1-7.
16. International Commission on Radiation Units. Prescribing, recording and reporting photon beam therapy. Supplement to ICRU Report 50. Bethesda: International Commission on Radi-ation Units and Measurement. MD: ICRU; 1999.
17. Feng FY, Kim HM, Lyden TH, Haxer MJ, Feng M, Worden FP, Chepeha DB, Eisbruch A: Intensity-modulated radiotherapy of head and neck cancer aiming to reduce dysphagia: early dose-effect relationships for the swallowing structures. Int J Radiat Oncol Phys. 2007; 68: 1289-1298.
18. Wang-Chesebro A, Xia P, Coleman J, Akazawa C, Roach M 3rd: Intensity-modulated radiotherapy improves lymph node cov-erage and dose to critical structures compared to with three-dimensional conformal radiation therapy in clinically lo-calized prostate cancer. Int J Radiat Oncol Phys. 2006; 66: 654-662.
19. Mundt AJ, Lujan AE, Rotmensch J, Waggoner SE, Yamada SD, Fleming G, Roeske JC: Intensity-modulated whole pelvic radi-otherapy in women with gynecologic malignancies. Int J Radiat Oncol Phys. 2002; 52:1330-1337.
20. Langen KM, Jones DT: Organ motion and its management. Int J Radiat Oncol Biol Phys. 2001; 50: 265-278.
21. Jaffray DA, Siewerdsen JH, Wong JW, Martinez AA: Flat-panel cone-beam computed tomography for image-guided radiation therapy. Int J Radiat Oncol Biol Phys. 2002; 53:1337-1349.
22. Gill S, Thomas J, Fox C, Kron T, Rolfo A, Leahy M, Chander S, Williams S, Tai KH, Duchesne GM, Foroudi F: Acute toxicity in prostate cancer patients treated with and without image-guided radiotherapy. Radiat Oncol. 2011; 6:145.
23. Duma MN, Kampfer S, Wilkens JJ, Schuster T, Molls M, Geinitz H. Comparative analysis of an image-guided versus a non-image-guided setup approach in terms of delivered dose to the parotid glands in head-and-neck cancer IMRT. Int J Radiat Oncol Biol Phys. 2010; 77: 1266-1273.
24. Barney BM, Lee RJ, Handrahan D, Welsh KT, Cook JT, Sause WT. Image-guided radiotherapy (IGRT) for prostate cancer comparing kV imaging of fiducial markers with cone beam computed tomography (CBCT). Int J Radiat Oncol Biol Phys. 2011; 80: 301-305.
25. Lo SS, Fakiris AJ, Chang EL, Mayr NA, Wang JZ, Papiez L, Teh BS, McGarry RC, Cardenes HR, Timmerman RD: Stereotactic body radiation therapy: a novel treatment modality. Nat Rev Clin Oncol. 2010; 7: 44-54.
26. Tipton K, Launders JH, Inamdar R, Miyamoto C, Schoelles K: Stereotactic body radiation therapy: scope of the literature. Ann Intern Med. 2011; 154: 737-745.
27. Lo SS, Moffatt-Bruce SD, Dawson LA, Schwarz RE, Teh BS, Mayr NA, Lu JJ, Grecula JC, Olencki TE, Timmerman RD: The role of local therapy in the management of lung and liver oli-gometastases. Nat Rev Clin Oncol. 2011; 8: 405-416.
28. Wu QJ, Wang Z, and Yin FF: The impact of respiratory motion and treatment technique on stereotactic body radiation therapy for liver cancer. Med Phys. 2008; 35: 1440-1451.
29. National radiotherapy implementation group report. Stereo-tactic body radiotherapy; Clinical review of the evidence for SBRT. UK: NRIG. 2010
30. Freeman DE, King CR: Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomes. Radiat Oncol. 2011; 6: 3.
31. Laramore GE: Role of particle radiotherapy in the management of head and neck cancer. Current Opin Oncol. 2009; 21: 224-231.
32. Schulz-Ertner D, Tsujii H: Particle radiation therapy using proton and heavier ion beams. J Clin Oncol. 2007; 25: 953-964.
33. Ma CM, Maughan RL: Within the next decade conventional cyclotrons for proton radiotherapy will become obsolete and replaced by far less expensive machines using compact laser systems for the acceleration of the protons. Med Phys. 2006; 33: 571-573.
34. Hall EJ: Cancer caused by x-rays-a random event? Lancet On-col. 2007; 8: 369-370.
35. Baskar R: Emerging role of radiation induced bystander effects: Cell communications and carcinogenesis. Genome Integr. 2010; 1: 13.
36. Emami B, Lyman J, Brown A, Coia L, Goitein M, Munzenrider JE, Shank B, Solin LJ, Wesson M: Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991; 21: 109-122.
37. Verheij M: Clinical biomarkers and imaging for radiothera-py-induced cell death. Cancer Metastasis Rev. 2008; 27: 471-480.
38. Dewey WC, Ling CC, Meyn RE: Radiation-induced apoptosis: relevance to radiotherapy. Int J Radiat Oncol Biol Phys. 1995; 33: 781-796.
39. Rupnow BA, Knox SJ: The role of radiation-induced apoptosis as a determinant of tumor responses to radiation therapy. Apoptosis 1999; 4: 115-143.
40. Cragg MS, Harris C, Strasser A, Scott CL: Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics. Nat Rev Cancer 2009; 9: 321-326.
41. Fogg VC, Lanning NJ, MacKeigan JP: Mitochondria in cancer: at the crossroads of life and death. Chin J Cancer 2011; 30: 526-539.
42. Eriksson D, Stigbrand T: Radiation-induced cell death mecha-nisms. Tumour Biol. 2010; 31: 363-372.
43. Sato N, Mizumoto K, Nakamura M, Ueno H, Minamishima YA, Farber JL, Tanaka M: A possible role for centrosome overdu-plication in radiation-induced cell death. Oncogene 2000; 19: 5281-5290.
44. Vakifahmetoglu H, Olsson M, Zhivotovsky B: Death through a tragedy: mitotic catastrophe. Cell Death Differ. 2008; 15: 1153-1162.
45. Jonathan EC, Bernhard EJ, McKenna WG: How does radiation kill cells? Curr Opin Chem Biol. 1999; 3: 77-83.
46. Hotchkiss RS, Strasser A, McDunn JE, Swanson PE: Cell death. N Engl J Med. 2009; 361: 1570-1583.
47. Roninson I: Tumor cell senescence in cancer treatment. Cancer Res. 2003; 63: 2705-2715.
48. Schmitt CA: Cellular senescence and cancer treatment. Biochim Biophys Acta. 2007; 1775: 5-20.
49. Ito H, Daido S, Kanzawa T, Kondo S, Kondo Y: Radia-tion-induced autophagy is associated with LC3 and its inhibi-tion sensitizes malignant glioma cells. Int J Oncol. 2005; 26: 1401-1410.
50. Kuwahara Y, Oikawa T, Ochiai Y, Roudkenar MH, Fukumoto M, Shimura T, Ohtake Y, Ohkubo Y, Mori S, Uchiyama Y, Fu-kumoto M: Enhancement of autophagy is a potential modality for tumors refractory to radiotherapy. Cell Death Dis. 2011; 2: e177. doi: 10.1038/cddis.2011.56.
51. Schmitt CA: Senescence, apoptosis and therapy-cutting the lifelines of cancer. Nat Rev Cancer 2003; 3: 286-295.
52. Vakifahmetoglu H, Olsson M, Zhivotovsky B: Death through a tragedy: mitotic catastrophe. Cell Death Differ. 2008; 15: 1153-1162.
53. Brandsma D, Stalpers L, Taal W, Sminia P, van den Bent MJ: Clinical features, mechanisms, and management of pseudo-progression in malignant gliomas. Lancet Oncol. 2008; 9: 453-461.
54. Schmitt CA, Fridman JS, Yang M, Lee S, Baranov E, Hoffman RM, Lowe SW: A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 2002; 109: 335-346.
55. Kondo Y, Kanzawa T, Sawaya R, Kondo S: The role of autoph-agy in cancer development and response to therapy. Nat Rev Cancer 2005; 5: 726-734.
56. Starmans MH, Zips D, Wouters BG, Baumann M, Lambin P: The use of a comprehensive tumour xenograft dataset to vali-date gene signatures relevant for radiation response. Radiother Oncol. 2009; 92: 417-422.
57. Brown JM: Therapeutic targets in radiotherapy. Int J Radiat Oncol Biol Phys. 2001; 49: 319-326.
58. Tofilon PJ, Saxman S, Coleman CN: Molecular targets for radi-ation therapy: bringing preclinical data into clinical trials. Clin Cancer Res. 2003; 9: 3518-3520.